Strengths and Weaknesses of TB Drug Management
Download
1 / 7

Power Point - PowerPoint PPT Presentation


  • 400 Views
  • Updated On :

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin. Group 1 Countries. Uganda Democratic Republic of Congo Congo Brazzaville Nigeria Benin Republic. Policy and Legal Framework: Strengths.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Power Point' - KeelyKia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide1 l.jpg

Strengths and Weaknesses of TB Drug Management

Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin


Slide2 l.jpg

Group 1 Countries

  • Uganda

  • Democratic Republic of Congo

  • Congo Brazzaville

  • Nigeria

  • Benin Republic


Slide3 l.jpg

Policy and Legal Framework: Strengths

  • NDP is present in all countries. In Congo Brazzaville, it is developed but not implemented.

  • Most countries have TB drugs on the EDL (except DRC).

  • Special consideration for donated drugs; all require evidence of quality control (+, -).


Slide4 l.jpg

Policy and Legal Framework: Weaknesses

  • Weak enforcement of policies, also in the private sector

  • Labs for QC not adequate

  • DOTS not widespread (except Benin)

  • Government funding levels inadequate (except Benin)


Slide5 l.jpg

Selection Process

  • All countries have protocols (STGs), however each country’s STGs may differ

    • Weakness: Forms and dosages differ within country

  • Regimen changes have been successful

    • Weakness: Problems with wastage


Slide6 l.jpg

Distribution and Use

  • All NTP involved in quantification

    • Weakness: Data questionable (except Benin, CB)

  • Drug management information systems are sometimes weak

  • Movement of drugs from the central to the regional level works well

    • Weakness: Movement from the regional to peripheral level is a problem


Slide7 l.jpg

Distribution and Use, continued

  • Use of blister packs has improved compliance and reduced wastage (Nigeria, Uganda)


ad